Latest Articles
Essex teen says endometriosis shouldn't be 'taboo' as she shares her story - Halstead Gazette
Essex teen says endometriosis shouldn't be 'taboo' as she shares her story Halstead Gazette
Published: Dec. 4, 2024, 9:01 a.m.
Essex teen says endometriosis shouldn't be 'taboo' as she shares her story - Clacton and Frinton Gazette
Essex teen says endometriosis shouldn't be 'taboo' as she shares her story Clacton and Frinton Gazette
Published: Dec. 4, 2024, 9:01 a.m.
Endometriosis, fibroids and heavy periods: long-term research supports treatment decisions - NIHR Evidence
Endometriosis, fibroids and heavy periods: long-term research supports treatment decisions NIHR Evidence
Published: Dec. 4, 2024, 8 a.m.
Endometriosis: ‘It’s so frustrating and isolating to know there’s something wrong with your body but to not be believed’ - The Irish Times
Endometriosis: ‘It’s so frustrating and isolating to know there’s something wrong with your body but to not be believed’ The Irish Times
Published: Dec. 4, 2024, 6:02 a.m.
Endometriosis: ‘If I was believed 10 years ago, maybe it wouldn’t be this extensive’ - The Irish Times
Endometriosis: ‘If I was believed 10 years ago, maybe it wouldn’t be this extensive’ The Irish Times
Published: Dec. 4, 2024, 6:02 a.m.
Why managing mould could be the secret to optimising your health - Women's Health
Why managing mould could be the secret to optimising your health Women's Health
Published: Dec. 4, 2024, 3:41 a.m.
What is Visanne, the endometriosis drug just added to the PBS? - New Zealand Doctor Online
What is Visanne, the endometriosis drug just added to the PBS? New Zealand Doctor Online
Published: Dec. 4, 2024, 1:33 a.m.
New research links depression to more painful periods - Fast Company
New research links depression to more painful periods Fast Company
Published: Dec. 3, 2024, 9:02 p.m.
Elagolix with add-back therapy found effective and tolerable for endometriosis pain - Contemporary Obgyn
Elagolix with add-back therapy found effective and tolerable for endometriosis pain Contemporary Obgyn
Published: Dec. 3, 2024, 6:36 p.m.
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer - OncLive
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer OncLive
Published: Dec. 3, 2024, 5:11 p.m.
Link copied to clipboard!